Drug profile · INN
omalizumab
OMLYCLO
omalizumab (OMLYCLO) is a ig epsilon chain c region inhibitor. Associated with Novartis Pharmaceuticals. Current US regulatory status: approved.
Drug details — omalizumab
- US status
- approved
- Class
- Respiratory system (R03)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
omalizumab (OMLYCLO) is a ig epsilon chain c region inhibitor. Associated with Novartis Pharmaceuticals. Current US regulatory status: approved.
Key facts
Mechanism of action
Ig epsilon chain C region inhibitor
Primary target: Immunoglobulin heavy constant epsilon
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is omalizumab?
omalizumab (OMLYCLO) is a ig epsilon chain c region inhibitor. Associated with Novartis Pharmaceuticals. Current US regulatory status: approved.
What is the brand name for omalizumab?
OMLYCLO is a marketed brand name for omalizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omalizumab?
omalizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.